The president claimed his “most-favored nation” proposal would reduce some pharmaceutical prices by as much as 80%, but the ...

While venture funding is rising, federal policy upheaval may affect women’s health research more acutely than other fields, ...

The failure is the latest stumble for a cancer drug class that hasn’t lived up to expectations. iTeos will begin a strategic ...

Having now appointed Henry Gosebruch as CEO of the intact company, Galapagos says its priorities are exploring strategic ...

Witty’s departure was unexpected, but follows a downturn in the healthcare company’s financial outlook. He will be replaced ...

Improvements in our understanding of the human genome, technological tools like artificial intelligence, and global ...

Reports of severe adverse events in some people who received the chikungunya vaccine have spurred regulators in Europe and ...

The biotech has quickly turned a cell therapy approval into one of the more lucrative recent sales for a priority review ...

The proposal would see the HHS set price targets other countries pay for certain medicines, kicking off a round of ...

The startup’s first prospect is a heart medicine that works differently than the hypertrophic cardiomyopathy drugs developed ...

The company added to a recent flurry of pledges by pharmaceutical companies, promising $11 billion in new capital and ...

A version of meloxicam designed to work faster has beat out a placebo in two late-stage studies focused on post-surgical ...